The year 2026 marks the mainstream arrival of Non-Steroidal Mineralocorticoid Receptor Antagonists (ns-MRAs), a breakthrough that is rewriting the playbook for Chronic Kidney Disease (CKD) and Diabetes management. Unlike older "steroidal" diuretics, these 2026 formulations target the heart and kidneys more precisely, significantly reducing the risk of systemic side effects. This is a...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
